Cinclus read-x: Voquezna CP win secures 2032 exclusivity
On Friday, Phathom's Voquezna (vonoprazan) has been granted its Citizen Petition (CP), securing 10-year exclusivity through 2032. This follows months of uncertainty after the FDA initially failed to reflect the full exclusivity (5 years NCE + 5 years GAIN) in the Orange Book, similar to the Voquezn
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.